Clinical Trial: NCT05799274
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | Radiopharm Theranostics, Ltd |
| Information Provided By: | Radiopharm Theranostics, Ltd |
| Last Update Posted: | 2026-09-14 |
Study Overview
Brief Summary
This is a Phase 1a, open label, single dose, extended study of safety and biokinetics of RAD301 in healthy human volunteers and individuals with PDAC or Other Solid Tumors
Official Title
Characterizing the Radiochemical and Radiation Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Ductal Adenocarcinoma or Other Solid Tumors
Conditions
Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma, Cervical Cancer, Endometrial Cancer, Ovarian Cancer
Intervention / Treatment
- Drug: RAD301 ([68Ga]-RAD301)
Other Study ID Numbers
- RAD301.2022-001
Start Date (Actual)
2023-11-09
Primary Completion Date (Estimated)
2026-09
Study Completion Date (Estimated)
2026-09
Enrollment (Estimated)
9
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Radiopharm Theranostics, Ltd |
| Information Provided By: | Radiopharm Theranostics, Ltd |
| Last Update Posted: | 2026-09-14 |
Study Overview
Brief Summary
This is a Phase 1a, open label, single dose, extended study of safety and biokinetics of RAD301 in healthy human volunteers and individuals with PDAC or Other Solid Tumors
Official Title
Characterizing the Radiochemical and Radiation Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Ductal Adenocarcinoma or Other Solid Tumors
Conditions
Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma, Cervical Cancer, Endometrial Cancer, Ovarian Cancer
Intervention / Treatment
- Drug: RAD301 ([68Ga]-RAD301)
Other Study ID Numbers
- RAD301.2022-001
Start Date (Actual)
2023-11-09
Primary Completion Date (Estimated)
2026-09
Study Completion Date (Estimated)
2026-09
Enrollment (Estimated)
9
Study Type
Interventional
Phase
Phase 1